Product/Composition:- | Gadodiamide Injectable Solution |
---|---|
Strength:- | 0.5 mol/L |
Form:- | Injectable Solution |
Reference Brands:- | Omniscan(U & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Gadodiamide is a gadolinium-based contrast agent that enhances MRI scans by increasing tissue radiopacity. It improves visualization of blood vessels, organs, and abnormalities, supporting accurate diagnosis. Benefits include high image quality, rapid excretion, safety, and detailed imaging support in neurological, cardiovascular, and musculoskeletal diagnostics worldwide.
Gadodiamide, marketed as Omniscan, is approved in the US by the FDA and in the EU via EMA for MRI contrast enhancement of neurological, cardiovascular, and musculoskeletal imaging. Regulatory approval requires a comprehensive dossier including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. The FDA reviews clinical trial and quality data for timely approval, while the EMA ensures compliance with regional safety and manufacturing standards. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Proper adherence to regional regulations supports swift approval, safe use, and global availability, facilitating high-quality diagnostic imaging worldwide.